Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 5Carcinoma, Non-Small-Cell Lung 2Carcinoma, Neuroendocrine 2Solid Tumors 1Solid Tumor Cancer 1Progression Free Survival 1Intracranial Germ Cell CNS Tumor, Childhood 1Hormone Refractory Prostate Cancer 1Carcinoma 1

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Irinotecan 7Bevacizumab 7Injections 6Cetuximab 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5Capecitabine 5tocilizumab 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3pazopanib 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Tumors × PE regimen × Clear all
NCT00878449 2018-06-06

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

AbbVie

Phase 1 Completed
12 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡